The dermal filler category splits into two fundamentally different mechanisms. Hyaluronic acid fillers — Juvéderm, Restylane, RHA, Belotero — occupy space immediately. They sit in the tissue as a cross-linked gel, attracting water and providing volume the moment they are injected. When the result is wrong, they can be dissolved with hyaluronidase.
Biostimulators — Sculptra (poly-L-lactic acid, PLLA), Radiesse (calcium hydroxylapatite, CaHA), Bellafill (polymethylmethacrylate, PMMA) — work differently. The injected material acts as a scaffold that triggers a controlled inflammatory response, recruiting fibroblasts to deposit new collagen around the microspheres. The volume you see long-term comes from your own collagen, not the injected material itself. And there is no enzyme to reverse it if something goes wrong.
ISAPS data show that PLLA procedures surged 430.7% from 2020 to 2024. The aesthetic injectables market is projected to grow from $13.97 billion in 2025 to $29.14 billion by 2032. Both trends reflect a shift toward regenerative approaches — but the shift brings tradeoffs that marketing does not always surface.
This article is about those tradeoffs: what each mechanism actually does, how the timelines differ, what the complication data show, and which patients are better served by one approach over the other.
Mechanism: physical volume vs. collagen scaffold
HA fillers are glycosaminoglycan gels cross-linked to varying densities. They hold up to 1,000 times their weight in water. They do not stimulate meaningful collagen production — they are space-occupying agents that create volume by physically being there. Different products in the same family are engineered for different depths and tissue planes: Juvéderm Voluma (high G', deep supraperiosteal) for cheeks, Juvéderm Ultra (lower G', more superficial) for lips and nasolabial folds, Belotero Balance (very low G', integrated into the superficial dermis) for fine lines.
PLLA (Sculptra) particles are made of poly-L-lactic acid, a biodegradable polymer used in medical applications since 1999. When injected into the deep dermis or subcutis, the particles trigger a foreign-body response that recruits fibroblasts. Collagen is deposited around the PLLA particles over 60–80 days. The PLLA is eventually bioabsorbed, leaving behind a collagen network. Sculptra was originally FDA-approved in August 2004 for HIV-associated facial lipoatrophy and received cosmetic approval for nasolabial fold correction on July 28, 2009.
CaHA (Radiesse) consists of calcium hydroxylapatite microspheres (24–45 micrometers) suspended in a sodium carboxymethylcellulose gel carrier. The gel provides immediate volume; the CaHA microspheres remain as the gel is metabolized, stimulating neocollagenesis. A 2024 preclinical study by Nowag et al. in the Journal of Cosmetic Dermatology found that CaHA triggers a more regenerative, non-inflammatory macrophage response compared to PLLA, which tends to induce a characteristic foreign-body inflammatory response. This may partly explain the different complication profiles observed clinically.
PMMA (Bellafill) is non-biodegradable — the microspheres remain permanently. It provides permanent structural support but also carries the highest granuloma risk and longest latency for complications. A 2025 systematic review in the Journal of Cosmetic Dermatology found PMMA accounted for 35% of reported foreign-body granuloma cases, with median onset at 35 months and cases appearing up to 15 years post-injection.
Timeline: when you see results
This is the single biggest patient-facing difference.
HA fillers produce visible results immediately. There is some swelling in the first 24–72 hours, but the contour change is apparent right away. Duration ranges from 6 to 24 months depending on the product, the treatment area, and the patient's metabolism. Juvéderm Voluma can last up to 18–24 months in the cheeks; lighter products like Restylane Silk may last 6 months in the lips.
Sculptra (PLLA) has a multi-phase timeline that patients must understand before treatment:
- Days 1–5: Apparent fullness is swelling and the water used to reconstitute the product. It resolves.
- Weeks 1–3: The "quiet phase." Swelling is gone, and it looks like nothing happened. PLLA particles are recruiting fibroblasts below the surface.
- Weeks 4–8: Subtle volume changes begin. This is when session 2 is typically scheduled.
- Months 2–6: Collagen production accelerates. Each session compounds the effect.
- Months 6–24+: Results mature and can last 2+ years. Some patients report persistent improvement at 5–7 years in certain areas.
The standard protocol is 3–4 sessions spaced 4–6 weeks apart, with the 5-5-5 massage rule (5 minutes, 5 times per day, for 5 days post-injection) to distribute particles evenly.
Radiesse (CaHA) offers a hybrid timeline:
- Days 1–7: Immediate volume from the gel carrier.
- Weeks 2–4: Gel absorbs; slight reduction from the initial result is normal as fibroblast activation begins.
- Months 1–3: The "collagen crossover" — newly formed collagen begins replacing the gel support.
- Months 3–18+: Results transition to collagen-supported. Evidence Level II studies show longevity of 30+ months in nasolabial folds, with 40% of treated folds maintaining improvement at that mark.
Typically a single session; touch-ups at 12–18 months.
Reversibility: the asymmetric risk
HA fillers can be dissolved with hyaluronidase, an enzyme that breaks down hyaluronic acid by cleaving the glycosidic bonds between N-acetylglucosamine and D-glucuronic acid. The enzyme has a short half-life in tissue — it is largely deactivated within about one hour — and works within 24–48 hours. HA filler has been successfully dissolved 63 months after injection (Woodward et al., 2015).
Different HA products dissolve at different rates. Belotero dissolves fastest; Juvéderm Voluma and Restylane Lyft are the slowest, because higher HA concentration, larger particle size, and increased cross-linking create more substrate that the enzyme must cleave.
The allergic reaction rate to hyaluronidase is low but real: 0.05–0.69% for local reactions, less than 0.1% for urticaria or angioedema. Patients with bee-venom allergy are at higher risk, because bee venom contains hyaluronidase.
Biostimulators cannot be reversed. There is no enzyme equivalent to hyaluronidase for PLLA, CaHA, or PMMA. This is the most important tradeoff in the entire category, and it is the one patients least understand.
For CaHA nodules, sodium thiosulfate has shown potential to partially disintegrate CaHA microspheres — but this is not a rapid, reliable reversal like hyaluronidase. For PLLA nodules, hyaluronidase can dissolve any HA carrier component but does not affect the PLLA particles themselves.
Early non-inflammatory nodules from particle clumping may respond to massage, mechanical vibration, or dilute saline injection. Late-stage inflammatory granulomas require intralesional corticosteroids (used in 21% of treated cases in a 2025 systematic review), 5-fluorouracil, or oral immunomodulators (minocycline, allopurinol, colchicine). Surgical excision is a last resort and is often incomplete because granulomas infiltrate surrounding tissue.
Complication data: what the evidence shows
A 2025 systematic review by Wang et al. in the Journal of Cosmetic Dermatology analyzed 40 studies covering 117 patients with foreign-body granulomas from collagen-stimulatory fillers. The findings are the most comprehensive complication dataset available for this product category:
- PMMA (Bellafill): 35% of reported granuloma cases, median onset 35 months, range up to 15 years
- PLLA (Sculptra): 31% of cases, median onset 19 months
- CaHA (Radiesse): 27% of cases, median onset 7 months
- PCL (Ellanse): 4% of cases, median onset 13 months
The most frequent presenting complication was nodules (83%), followed by swelling (9%) and lumps (3%). The highest-risk injection sites were perioral and oral areas (31% of granulomas). Key risk factors: too-superficial injection, high microsphere concentration, inadequate massage, excessive dose, insufficient intervals between sessions, and incorrect preparation or hydration time.
Treatment outcomes were sobering: nodule remission in 27%, complete resolution in 10%, with 55% of patients lost to follow-up.
For HA fillers, the complication profile is different in kind. Vascular occlusion occurs at approximately 0.001% of treatments and is treatable with high-dose hyaluronidase (450–1,500 units infiltrated over the area, repeated hourly for up to 4 cycles). The Tyndall effect — a bluish hue from superficial placement — is treatable. Delayed-onset nodules are often manageable with hyaluronidase plus antibiotics. Blindness from periocular embolism is rare but devastating and is a medical emergency where retrobulbar hyaluronidase (150–200 units) is rarely successful.
The asymmetry matters: HA complications are more frequent in the short term but more manageable; biostimulator complications are less frequent per injection but far more persistent and harder to treat when they occur.
Patient fit: who gets what
Best candidates for HA fillers:
- Need immediate, visible results
- Want precise, targeted volumization (lips, tear troughs, specific wrinkles)
- Value reversibility and the ability to adjust
- Have localized volume loss rather than diffuse aging
- Are filler-naive and want to see what filler looks like before committing
- Need treatment in anatomically unforgiving areas (periocular, lips) where biostimulators carry higher nodule risk
Best candidates for biostimulators:
- Diffuse facial volume loss, particularly temples, cheeks, jawline
- Want gradual, natural-looking transformation
- Willing to accept delayed results (especially Sculptra)
- Seeking longer-lasting results (12–30+ months)
- Good skin quality with early-to-moderate volume loss
- Are not seeking lip augmentation — CaHA is not recommended for lips due to nodule risk
- GLP-1–related facial volume loss — biostimulators are increasingly positioned as the primary approach for diffuse volume depletion after semaglutide or tirzepatide use, because the volume loss is typically widespread rather than localized
GLP-1 facial volume loss: where biostimulators fit
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjuro, Zepbound) produce significant weight loss in many patients, and with it, widespread facial fat depletion. The clinical presentation is different from age-related volume loss: it is diffuse, rapid, and often affects patients who are younger than the typical filler demographic.
HA fillers can address specific hollows — tear troughs, cheeks, temples — but they do not solve the underlying diffuse deflation. Biostimulators, particularly Sculptra, are being used to rebuild facial volume through collagen production across larger surface areas. ASPS has noted that Sculptra is "great in Ozempic patients" because it "can naturally enhance the entire cheek and provide a graceful fullness." The typical approach is a hybrid protocol: HA filler for targeted hollows, Sculptra for comprehensive structural rebuilding over 3–4 sessions.
This is an emerging use case. Long-term outcome data on biostimulator treatment specifically in the GLP-1 weight-loss population are not yet published, and patients should be aware that the evidence base here is clinical experience rather than controlled trials.
Off-face applications
CaHA and PLLA are not limited to the face. Hyperdiluted CaHA (Radiesse diluted 1:1 to 1:4 with saline or lidocaine) is used for skin quality improvement on the neck, chest (decolletage), and hands, where the goal is collagen stimulation and dermal thickening rather than volumization. The dilution reduces nodule risk and enables broader tissue integration. PLLA is used off-face for buttock augmentation — the second most common PLLA application in the US — as well as for abdomen, thighs, and cellulite treatment. These off-face applications use the same collagen-stimulating mechanism but with different dilution ratios, injection techniques, and volume ranges than facial treatment.
The hyperdilution technique is worth understanding because it changes the product's behavior: lower particle concentration per unit volume means less volumization but more even collagen distribution, which is why it is used for skin quality rather than structural support.
Hybrid protocols are increasingly the 2026 standard: HA filler for immediate structural support in specific zones (mid-face, lips) combined with a biostimulator for long-term collagen building and diffuse volume restoration. CaHA patient satisfaction data show 93.5% satisfaction (58/62 patients in one study), suggesting that when patient selection is right, the outcomes are strong.
Cost comparison
HA fillers run $500–$1,000+ per syringe depending on formulation, typically 1–2 syringes per area, with re-treatment every 6–18 months. Radiesse is comparable at roughly $717 per syringe. Sculptra is the most expensive upfront: $800–$1,200 per vial, with a full protocol requiring 3–4 vials over the treatment course ($2,400–$4,800+ total).
Over time, the cost equation shifts. A biostimulator that lasts 24–30 months may cost less over a 3-year horizon than HA filler requiring 2–3 re-treatment cycles in the same period. But the upfront commitment is real, and approximately 30% of potential PLLA patients cite cost as a barrier.
What to ask before choosing
- Is my volume loss localized (better for HA) or diffuse (better for biostimulator)?
- Do I need results now, or can I wait 2–6 months for collagen to build?
- Is reversibility important to me? If so, HA is the only option with a reliable reversal agent.
- What areas am I treating? Lips and tear troughs are generally not appropriate for biostimulators.
- How many sessions am I prepared for? Sculptra requires 3–4; Radiesse is typically 1.
- What is the total cost over 2–3 years, not just the first session?
Sources
- Wang H, Wu D, Lo C, et al. "Foreign body granulomas reaction related to collagen stimulatory cosmetic fillers: a systematic review." J Cosmet Dermatol. 2025;24(10):e70459. https://pmc.ncbi.nlm.nih.gov/articles/PMC12550546/
- King M, Convery C, Davies E. "The Use of Hyaluronidase in Aesthetic Practice (v2.4)." J Clin Aesthet Dermatol. 2018;11(6):E61-E68. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011868/
- Nowag B, et al. "Biostimulating fillers and induction of inflammatory pathways: A preclinical investigation of macrophage response to calcium hydroxylapatite and poly-L lactic acid." J Cosmet Dermatol. 2024;23:99-106. https://doi.org/10.1111/jocd.15928
- FDA Summary of Safety and Effectiveness Data (SSED) for Sculptra Aesthetic (P030050/S002). https://www.accessdata.fda.gov/cdrh_docs/pdf3/p030050s002b.pdf
- Bass L, et al. "Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results." Aesthet Surg J. 2010;30(2):235-238. https://doi.org/10.1177/1090820X10366549
- Hong JY, Park KY. "Dual Benefits of Calcium Hydroxyapatite Filler: A Prospective Study on Midface Volume Restoration and Skin Quality Enhancement." J Cosmet Dermatol. 2025;24(6):e70265. https://pmc.ncbi.nlm.nih.gov/articles/PMC12121328/
- Goldie K, et al. "Consensus Agreements on Regenerative Aesthetics: A Focus on Regenerative Biostimulation With Calcium Hydroxylapatite." Dermatologic Surgery. 2024;50(11 Suppl):S172-S176.
- ISAPS 2024 Global Survey. International Society of Aesthetic Plastic Surgery. June 2025. https://isaps.org/media/razfvmsk/isaps-global-survey-2024.pdf
